GHRP-2


Growth hormone releasing peptide / ghrelin receptor agonist

A second-generation hexapeptide ghrelin receptor agonist for growth hormone release, characterized by stronger GH stimulation than GHRP-6 with reduced cortisol/prolactin elevation.

Abstract

GHRP-2 (Pralmorelin; D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2; CAS 158861-67-7; molecular formula C45H55N9O6; molecular weight 817.97) is a second-generation growth hormone releasing peptide developed in the 1990s as a synthetic ghrelin receptor (GHS-R1a) agonist. The compound stimulates pituitary GH release through a mechanism distinct from GHRH (different receptor; synergistic when combined with GHRH or GHRH analogs). GHRP-2 produces robust GH pulses approximately 2 to 5 times baseline with parenteral administration. Pharmacokinetics: plasma half-life 15 to 60 minutes; subcutaneous and intravenous routes; oral bioavailability poor due to peptidase degradation. The compound is used clinically in Japan as a GH stimulation test. Compared with GHRP-6, GHRP-2 produces stronger GH release with reduced cortisol and prolactin elevation. Compared with ipamorelin, GHRP-2 has higher GH efficacy but less receptor selectivity.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph